These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28390105)

  • 1. Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report.
    Tanaka S; Haketa A; Yamamuro S; Suzuki T; Kobayashi H; Hatanaka Y; Ueno T; Fukuda N; Abe M; Yoshino A; Soma M
    J Diabetes Investig; 2018 Jan; 9(1):223-225. PubMed ID: 28390105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient.
    Webb SM; Ortega E; Rodríguez-Espinosa J; Mato ME; Corcoy R
    Pituitary; 2001 Sep; 4(4):275-8. PubMed ID: 12501980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on lanreotide Autogel in acromegaly.
    Croxtall JD; Scott LJ
    BioDrugs; 2008; 22(4):275-7. PubMed ID: 18611070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
    Chanson P; Leselbaum A; Blumberg J; Schaison G
    Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly.
    Lin JD; Lee ST; Weng HF
    Endocr J; 1999 Feb; 46(1):193-8. PubMed ID: 10426587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanreotide for the treatment of acromegaly.
    Castinetti F; Saveanu A; Morange I; Brue T
    Adv Ther; 2009 Jun; 26(6):600-12. PubMed ID: 19533047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical results of long-term slow-release lanreotide treatment of acromegaly.
    Giusti M; Ciccarelli E; Dallabonzana D; Delitala G; Faglia G; Liuzzi A; Gussoni G; Giordano Disem G
    Eur J Clin Invest; 1997 Apr; 27(4):277-84. PubMed ID: 9134375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance.
    Pereira AM; Biermasz NR; Roelfsema F; Romijn JA
    Treat Endocrinol; 2005; 4(1):43-53. PubMed ID: 15649100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study.
    Caron PJ; Petersenn S; Houchard A; Sert C; Bevan JS;
    Clin Endocrinol (Oxf); 2017 Apr; 86(4):541-551. PubMed ID: 27874199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
    Jenkins PJ; Akker S; Chew SL; Besser GM; Monson JP; Grossman AB
    Clin Endocrinol (Oxf); 2000 Dec; 53(6):719-24. PubMed ID: 11155094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
    Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
    Caron P; Morange-Ramos I; Cogne M; Jaquet P
    J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.
    Maiza JC; Castillo-Ros S; Matta M; Bennet A; Caron P
    Pituitary; 2012 Dec; 15 Suppl 1():S23-7. PubMed ID: 21221819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.